Abstract: The invention concerns an arrangement for determining the concentration of glucose in a tissue fluid. In the microdialysis technology used for this purpose, perfusate-containing glucose is transported in intermittent delivery pulses through a microdialysis probe inserted into the tissue fluid and dialysate obtained in this process is passed to a measuring cell to record the glucose content. In order to achieve an exact determination of glucose even with a reduced dialysis period, it is proposed that the starting content of glucose in the perfusate is adapted to the glucose content of the tissue fluid by means of a control device in accordance with a command variable derived from the measurement signals of the measuring cell. When the control deviation is negligible the momentary starting content of glucose in the perfusate can be determined as a measure for the glucose content of the tissue fluid.
Abstract: The present invention concerns processes for the production of dry, partially amorphous products containing biologically active and in particular therapeutically active material which are macroscopically homogeneous substance mixtures, the substance mixtures being selected from at least one substance of each of the groups (i) carbohydrate or zwitterion with a polar residue and derivatives thereof, and (ii) zwitterion with an apolar residue and derivatives thereof, wherein a solution is prepared of the biologically or therapeutically active material and of substances (i) and (ii) and the solution is dried at a product temperature above the freezing point of the solution. In addition the invention concerns new substance mixtures which are obtained by the said process as well as the use thereof in diagnostic or therapeutic methods.
Abstract: Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.
Type:
Application
Filed:
May 25, 2006
Publication date:
January 18, 2007
Applicant:
Roche Diagnostics, GMBH
Inventors:
Frank Seela, Helmut Rosemeyer, Enno Schweinberger, Dieter Heindl, Frank Bergmann
Abstract: An object is to provide a dispenser operation verification apparatus and verification method that enables operation with high reliability and high accuracy.
Type:
Application
Filed:
September 14, 2006
Publication date:
January 11, 2007
Applicants:
Precision System Science Co., Ltd., Roche Diagnostics GmbH
Abstract: An object is to provide a dispenser operation verification apparatus and verification method that enables operation with high reliability and high accuracy.
Type:
Grant
Filed:
December 27, 2000
Date of Patent:
January 9, 2007
Assignees:
Precision System Science, Co., Ltd., Roche Diagnostics GmbH
Abstract: The present invention relates to improved variants of soluble pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenases (s-GDH), to genes encoding mutated s-GDH, to mutant proteins of s-GDH with improved substrate specificity for glucose, and to different applications of these s-GDH variants, particularly for determining concentrations of sugar, especially of glucose in a sample.
Abstract: The present invention concerns a polypeptide which is composed of the amino acids 1207±10 to 1488±10 of a hepatitis C virus and of less than 20 foreign amino acids and the use of this polypeptide as an antigen in an immunological test.
Type:
Grant
Filed:
June 29, 2001
Date of Patent:
October 17, 2006
Assignee:
Roche Diagnostic GmbH
Inventors:
Christoph Seidel, Ursula-Henrike Wienhues, Urban Schmitt, Manfred Motz, Michael Wiedmann, Barbara Upmeier, Erwin Soutschek
Abstract: The invention concerns an analytical element for the determination of an analyte containing in or on material which enables liquid transport between zones, a sample application zone and a detection zone located downstream thereof, wherein the detection zone contains a partner 1 of a specific binding pair 1 immobilized in such a manner that it is able to bind to partner 2 of the specific binding pair 1 which is not the analyte when it contacts it, wherein a labelled partner 1 of a specific binding pair 2 is present upstream of the detection zone impregnated on a material such that it can be detached by liquid and is able to bind to partner 2 of the specific binding pair 2 which is not the analyte when this contacts it as well as a method for the determination of an analyte using this analytical element.
Type:
Grant
Filed:
December 30, 2003
Date of Patent:
October 10, 2006
Assignee:
Roche Diagnostics GmbH
Inventors:
Jürgen Klepp, Gerhard Hiller, Alfons Nichtl, Thomas Fischer, Martina Hösch
Abstract: Method for the detection of a nucleic acid comprising the production of a plurality of amplificates of a section of this nucleic acid with the aid of two primers, one of which can bind to a binding sequence A of the nucleic acid and the other can bind to a binding sequence C? which is complementary to a sequence C which is located in the 3? direction from A and does not overlap with A, contacting the amplificates with a probe having a binding sequence D which can bind to a sequence B which is located between the sequences A and C or to the complement thereof, and detecting the formation of a hybrid of the amplificate and probe where the sequence located between the binding sequences A and C contains no nucleotides that do not belong to the binding sequence D of the probe or its complement D?.
Type:
Grant
Filed:
December 17, 2002
Date of Patent:
September 12, 2006
Assignee:
Roche Diagnostics GmbH
Inventors:
Christoph Kessler, Gerd Haberhausen, Knut Bartl, Henrik Orum
Abstract: The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.
Type:
Application
Filed:
April 5, 2006
Publication date:
August 3, 2006
Applicant:
Roche Diagnostics GmbH
Inventors:
Josef Endl, Peter Stahl, Winfried Albert, Guenther-Gerhard Jung, Dolores Schendel, Edgar Meinl, Klaus Dornmair
Abstract: The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)n and with a content of below 1 EU/mg DNA of endotoxins. Said preparation is suitable as a drug particularly in gene therapy.
Abstract: The invention concerns a method for stabilizing the content of glycated protein in a sample on a matrix material, which is characterized in that the matrix material is impregnated with boric acid buffer with a pH which is larger or equal to 10.5 or a transition metal salt as well as an appropriate matrix material, an element for collecting, transporting and storing sample material to be analysed with such a matrix material and a system containing such an element and a sealable covering.
Abstract: A device for withdrawing blood for diagnostic purposes including a lancet and a lancet drive having a loadable elastic drive spring provided within an elongated housing. A relaxing motion of the drive spring is converted into a puncturing motion to move the lancet at high speed in a puncturing direction until its tip exits out of an opening of the housing. The device includes a transmission in the housing that has an input side that transforms the motion of a loading element along a linear loading path into a rotational motion of a lancet drive rotor to load the lancet drive rotor by tensioning the drive spring. When the lancet drive is triggered, the output side of the transmission converts a rotational motion of the lancet drive rotor, driven by the drive spring, into the puncturing motion in a direction along the main axis.
Abstract: The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.
Type:
Grant
Filed:
November 16, 1999
Date of Patent:
June 20, 2006
Assignee:
Roche Diagnostics GmbH
Inventors:
Josef Endl, Peter Stahl, Winfried Albert, Guenther-Gerhard Jung, Dolores J. Schendel, Edgar Meinl, Klaus Dornmair
Abstract: The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S rRNA genes, to be used for the specific detection and/or identification of Serratia species, in particular of Serratia marcescens, Serratia ficaria and/or Serratia fonticola, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Serratia species, in particular Serratia marcescens, Serratia ficaria and/or Serratia fonticola, using said new nucleic acid sequences derived from the ITS region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Serratia species in a sample.
Abstract: A purified thermostable enzyme is derived from the thermophilic archaebacterium Archaeoglobus fulgidus. The enzyme can be native or recombinant, is stable under PCR conditions and exhibits double strand specific exonuclease activity. It is a 3?–5? exonuclease and cleaves to produce 5?-mononucleotides. Thermostable exonucleases are useful in many recombinant DNA techniques, in combination with a thermostable DNA polymerase like Tag especially for nucleic acid amplification by the polymerase chain reaction (PCR).
Type:
Grant
Filed:
September 27, 2000
Date of Patent:
April 18, 2006
Assignees:
Roche Diagnostics GmbH, Roche Molecular Systems Inc.
Inventors:
Waltraud Ankenbauer, Frank Laue, Harald Sobek, Michael Greif
Abstract: A purified thermostable enzyme is derived form the thermophilic archaebacterium Archaeoglobus fulgidus. The enzyme can be native or recombinant, is stable under PCR conditions and exhibits double strand specific exonuclease activity. It is a 3?-5? exonuclease and cleaves to produce 5?-mononucleotides. Thermostable exonucleases are useful in many recombinant DNA techniques, in combination with a thermostable DNA polymerase like Taq especially for nucleic acid amplification by the polymerase chain reaction (PCR).
Type:
Application
Filed:
September 29, 2005
Publication date:
April 13, 2006
Applicants:
Roche Diagnostics GmbH, Roche Molecular Systems Inc.
Inventors:
Waltraud Ankenbauer, Frank Laue, Harald Sobek, Michael Greif
Abstract: The invention concerns an element for the determination of an analyte in a liquid by means of a specific binding reaction of two bioaffine binding partners containing in or on material which enables liquid transport between the zones. The element comprises a sample application zone; a detection zone located downstream thereof that is devoid of binding reagents and is the last zone on the element that allows liquid transport; a zone containing immobilized analyte or analyte analogue between the sample application zone and the detection zone; and impregnated conjugate that can be detached by liquid located in the sample application zone or upstream or downstream thereof composed of a bioaffine binding partner capable of a specific binding reaction with the analyte to be determined and a detectable label.
Type:
Grant
Filed:
June 15, 2000
Date of Patent:
April 11, 2006
Assignee:
Roche Diagnostics GmbH
Inventors:
Ada Goerlach-Graw, Reiner Schlipfenbacher
Abstract: A process is provided for the production of a surface coating as well as the use of surface coatings to increase the surface tension of objects. The surface coating is obtained by depositing a layer of at least one element that can be oxidized with water or an alloy that can be oxidized with water. Subsequently, the deposited layer is subjected to boiling water or water vapor. The element is generally derived from the following group of elements: Al, Si, Ti, V, Cr, Mn, Fe, Co, Ni, Zn, Ga, Ge, Zr, Nb, Cd, In, Sn, Sb.
Abstract: The invention concerns a process for optimizing the gene expression in cells. A first aspect concerns a process for changing the expression of a nucleic acid sequence which is present endogenously in a eukaryotic cell by introduction of a heterologous expression control sequence into the genome of the cell by means of homologous recombination as well as site-specific recombinase-mediated excision of inserted foreign DNA and its replacement by further heterologous expression control sequences or/and amplification genes. In addition the invention concerns the introduction of one or several nucleic acid sequences to which an activator protein or an activator protein complex binds e.g. a hypoxia-inducible factor (HIF), into the genome of a eukaryotic cell by homologous recombination in order to change the expression of a target gene.
Type:
Grant
Filed:
December 1, 1998
Date of Patent:
March 7, 2006
Assignee:
Roche Diagnostics GmbH
Inventors:
Konrad Honold, Thomas Holtschke, Anne Stern